Halozyme Announces FDA Approval of Roche's Tecentriq …
SAN DIEGO, Sept. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received U.S. Food and Drug Administration (FDA) approval for Tecentriq...
Halozyme Announces Positive Clinical Data of its High-Volume …
Oct 16, 2023 · Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE® drug delivery technology, in approximately 30 seconds.
News - Halozyme
2 days ago · Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications 12/30/2024
Halozyme Announces FDA Approval of Bristol Myers Squibb's …
Dec 30, 2024 · "We are pleased Opdivo Qvantig, which is co-formulated with our ENHANZE drug delivery technology, is now FDA-approved as the first and only subcutaneously administered PD-1 inhibitor in the...
Halozyme Announces Expansion of Global Collaboration and …
Four new targets nominated for total of six nominated targets, including FcRn (VYVGART® Hytrulo), for ENHANZE® drug delivery technology. Halozyme to receive total upfront payment of $30 million...
Halozyme’s ENHANZE® (HALO) Technology Empowers OCREVUS …
Sep 20, 2024 · Halozyme Therapeutics (NASDAQ: HALO), a leader in innovative drug delivery solutions, recently announced a significant milestone. Roche has secured FDA approval for OCREVUS ZUNOVO™, a subcutaneous formulation of OCREVUS that incorporates Halozyme’s groundbreaking ENHANZE® technology.
Halozyme Announces argenx's VYDURA with ENHANZE® was …
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated with Halozyme's ENHANZE ® drug delivery technology, was granted regulatory approval by Japan's Ministry of Health, Labour and Welfare (MHLW) for ad...
Halozyme Announces Issuance of New European Patent for ENHANZE…
Jun 5, 2024 · Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees.
Halozyme Announces FDA approval of Bristol Myers Squibb's …
Dec 30, 2024 · Halozyme Therapeutics, Inc announced that Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) co-formulated with Halozyme's ENHANZE® drug delivery technology for subcutaneous use in most previously approved adult, solid tumor intravenous (IV) Opdivo® indications as monotherapy, monotherapy maintenance ...
Halozyme: Bristol Myers Gets New PDUFA Date For ... - Markets …
May 21, 2024 · (RTTNews) - Halozyme Therapeutics, Inc. (HALO) said Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the FDA for their Biologics License Application for the...
- Some results have been removed